Genocea Biosciences Inc EBITDA margin
Cos'è EBITDA margin di Genocea Biosciences Inc?
EBITDA margin di Genocea Biosciences Inc è -2,788.23%
Qual è la definizione di EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin di aziende nel Health Care settore su NASDAQ rispetto a Genocea Biosciences Inc
Cosa fa Genocea Biosciences Inc?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Aziende con ebitda margin simili a Genocea Biosciences Inc
- Inovio Pharmaceuticals ha EBITDA margin di -2,850.67%
- WayPoint Biomedical ha EBITDA margin di -2,849.14%
- UroGen Pharma Ltd ha EBITDA margin di -2,821.65%
- Syros Pharmaceuticals ha EBITDA margin di -2,796.41%
- Saint Jean Carbon ha EBITDA margin di -2,796.21%
- Volt Carbon Technologies Inc ha EBITDA margin di -2,796.21%
- Genocea Biosciences Inc ha EBITDA margin di -2,788.23%
- AssetOwl ha EBITDA margin di -2,784.76%
- Sprott Physical Silver Trust ha EBITDA margin di -2,779.39%
- Nex Metals Explorations ha EBITDA margin di -2,766.11%
- Ascendis Pharma A/S ha EBITDA margin di -2,759.32%
- GobiMin ha EBITDA margin di -2,734.72%
- Transition Metals ha EBITDA margin di -2,718.30%